Article
Oncology
Alexandre Michaux, Sebastien Mauen, Eytan Breman, Marie-Sophie Dheur, Laure Twyffels, Laura Saerens, Celine Jacques-Hespel, Emilie Gauthy, Sophie Agaugue, David E. Gilham, Panagiota A. Sotiropoulou
Summary: The study demonstrated that interfering with TCR signaling by expressing a truncated CD3ζ peptide can generate allogeneic CAR T cells that are less likely to cause graft-versus-host disease. These CYAD-101 cells showed anti-tumor activity in vitro and in vivo, with high consistency in cell batches production, potentially suitable for clinical trials.
JOURNAL OF IMMUNOTHERAPY
(2022)
Article
Oncology
Michael Cecchini, Jeremy S. Kortmansky, Can Cui, Wei Wei, Jaykumar Ranchobdhai Thumar, Nataliya Uboha, Navid Hafez, Jill Lacy, Neal A. Fischbach, Kert D. Sabbath, Christina M. Gomez, Jonathan Reed Sporn, Stacey Stein, Howard S. Hochster
Summary: The combination therapy of TAS-102 and oxaliplatin was found to be safe and effective in metastatic colorectal cancer patients previously treated with oxaliplatin, without unexpected toxicities. Although the overall response rate was low, the treatment combination prolonged progression-free survival and overall survival.
Article
Hematology
Gareth P. Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina Wagner-Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J. Hernandez-Ilizaliturri, Andreas Klein, John M. Pagel, Witold Rybka, Andrew J. Yee, Anne Mohrbacher, Mo Huang, Mohammed Farooqui, Patricia Marinello, Hang Quach
Summary: This study demonstrates the potential therapeutic option of combining pembrolizumab, an anti-PD-1 inhibitor, with dinaciclib, a CDK9 inhibitor, in patients with relapsed or refractory CLL and DLBCL. The combination showed activity with a manageable safety profile, suggesting further exploration is warranted for anti-PD-1 and CDK9 inhibitor combinations.
Article
Oncology
Chung-Han Lee, Amishi Yogesh Shah, Drew Rasco, Arpit Rao, H. Matthew Taylor, Christopher Di Simone, J. James Hsieh, Alvaro Pinto, R. David Shaffer, Regina Girones Sarrio, Allen Lee Cohn, J. Nicholas Vogelzang, Mehmet Asim Bilen, Sara Gunnestad Ribe, Musaberk Goksel, Oyvind Krohn Tennoe, Donald Richards, F. Randy Sweis, Jay Courtright, Daniel Heinrich, Sharad Jain, Jane Wu, V. Emmett Schmidt, F. Rodolfo Perini, Peter Kubiak, E. Chinyere Okpara, D. Alan Smith, J. Robert Motzer
Summary: Combination therapy of lenvatinib plus pembrolizumab showed promising antitumor activity and manageable safety profile in patients with metastatic RCC, providing a potential option for post-ICI treatment.
Article
Urology & Nephrology
Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhofer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono
Summary: This study evaluated the efficacy and safety of pembrolizumab plus olaparib in previously treated patients with metastatic castration-resistant prostate cancer. The results demonstrated antitumor activity and expected safety of this combination therapy in patients.
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Hematology
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Ozcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
Summary: Previous analysis of the KEYNOTE-170 study showed that pembrolizumab was effective and safe in treating relapsed/refractory PMBCL patients who had disease progression after autologous stem cell transplantation or were ineligible for the procedure. The final analysis revealed that after 4 years of follow-up, pembrolizumab still demonstrated durable responses and promising trends for long-term survival, with acceptable safety.
Article
Urology & Nephrology
Evan Y. Yu, Michael P. Kolinsky, William R. Berry, Margitta Retz, Loic Mourey, Josep M. Piulats, Leonard J. Appleman, Emanuela Romano, Gwenaelle Gravis, Howard Gurney, Martin Bogemann, Urban Emmenegger, Anthony M. Joshua, Mark Linch, Srikala Sridhar, Henry J. Conter, Brigitte Laguerre, Christophe Massard, Xin Tong Li, Charles Schloss, Christian H. Poehlein, Johann S. de Bono
Summary: The study evaluated the efficacy and safety of pembrolizumab combined with docetaxel and prednisone in patients with mCRPC, showing promising antitumor activity and manageable safety in this patient population.
Article
Oncology
John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua D. Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham Kanate, Pier Luigi Zinzani, Jacob Bitran, Herve Ghesquieres, Stephen J. Schuster, Mohammed Farooqui, Patricia Marinello, Nancy L. Bartlett
Summary: The study evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL. The results showed that pembrolizumab had good efficacy in PMBCL in patients who were ineligible or failed hematopoietic cell transplantation, but its efficacy in other NHL subtypes was uncertain. Hematologic toxicities were common treatment-related adverse events.
LEUKEMIA & LYMPHOMA
(2023)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Nicola Personeni, Valeria Smiroldo, Emilio Francesco Giunta, Maria Giuseppina Prete, Lorenza Rimassa, Giacomo Bregni, Francesco Sclafani
Summary: Metastatic colorectal cancer (mCRC) poses significant challenges in cancer management, but advancements in precision medicine have led to more personalized treatment strategies. Innovative research on molecular pathways and emerging biomarkers is driving the development of targeted therapies for refractory mCRC, enhancing prognosis and treatment outcomes.
Article
Oncology
Luis A. Diaz, Kai-Keen Shiu, Tae-Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardiere, Fernando Rivera, Elena Elez, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David Fogelman, Patricia Marinello, Thierry Andre
Summary: The final overall survival analysis of the KEYNOTE-177 study showed that while pembrolizumab continued to demonstrate durable antitumor activity and fewer treatment-related adverse events compared to chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, there was no statistically significant difference in overall survival between the two treatment groups.
Article
Oncology
A. V. Balar, D. E. Castellano, P. Grivas, D. J. Vaughn, T. Powles, J. Vuky, Y. Fradet, J. -L. Lee, L. Fong, N. J. Vogelzang, M. A. Climent, A. Necchi, D. P. Petrylak, E. R. Plimack, J. Z. Xu, K. Imai, B. H. Moreno, J. Bellmunt, R. de Wit, P. H. O'Donnell
Summary: Immune checkpoint inhibitors are effective in treating metastatic urothelial carcinoma. Long-term follow-up is necessary to confirm the efficacy and safety of the treatment.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Hope S. Rugo, Peter Kabos, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J. Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney
Summary: This study investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The combination therapy demonstrated antitumor activity, but had high rates of ILD/pneumonitis and severe transaminase elevations, which does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.
Article
Oncology
Wei Cen Wang, Beatrice Preti, Nancy Read, Paul Gibson, Keith Kwan, Eric Winquist
Summary: This case illustrates the potential benefit of immunotherapy for improving survival and quality of life in selected patients with metastatic EBV-positive cisplatin-refractory NPC.
FRONTIERS IN ONCOLOGY
(2023)
